CN101379400A - 可溶性人m-csf受体及其应用 - Google Patents

可溶性人m-csf受体及其应用 Download PDF

Info

Publication number
CN101379400A
CN101379400A CNA2006800519125A CN200680051912A CN101379400A CN 101379400 A CN101379400 A CN 101379400A CN A2006800519125 A CNA2006800519125 A CN A2006800519125A CN 200680051912 A CN200680051912 A CN 200680051912A CN 101379400 A CN101379400 A CN 101379400A
Authority
CN
China
Prior art keywords
cancer
soluble
csf
csfr
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800519125A
Other languages
English (en)
Chinese (zh)
Inventor
C·刘
M·多特－莱因哈德
J·库尼奇
M·卡瓦诺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Xoma Technology Ltd USA
Original Assignee
Novartis AG
Xoma Technology Ltd USA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG, Xoma Technology Ltd USA filed Critical Novartis AG
Publication of CN101379400A publication Critical patent/CN101379400A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/53—Colony-stimulating factor [CSF]
    • G01N2333/535—Granulocyte CSF; Granulocyte-macrophage CSF

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CNA2006800519125A 2005-12-22 2006-12-21 可溶性人m-csf受体及其应用 Pending CN101379400A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75321805P 2005-12-22 2005-12-22
US60/753,218 2005-12-22
US60/786,131 2006-03-27

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201310429826.5A Division CN103558391A (zh) 2005-12-22 2006-12-21 可溶性人m-csf受体及其应用

Publications (1)

Publication Number Publication Date
CN101379400A true CN101379400A (zh) 2009-03-04

Family

ID=38609972

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800519125A Pending CN101379400A (zh) 2005-12-22 2006-12-21 可溶性人m-csf受体及其应用

Country Status (8)

Country Link
US (2) US20100099123A1 (https=)
EP (1) EP1977238B1 (https=)
JP (2) JP2009521685A (https=)
KR (1) KR101358600B1 (https=)
CN (1) CN101379400A (https=)
AU (1) AU2006342119B8 (https=)
CA (1) CA2634945A1 (https=)
WO (1) WO2007120252A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2427323C1 (ru) * 2010-02-25 2011-08-27 Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Федерального агентства по высокотехнологичной медицинской помощи" Способ прогнозирования генерализации процесса при злокачественных опухолях костей

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8080246B2 (en) 2008-11-26 2011-12-20 Five Prime Therapeutics, Inc. Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules
WO2010062401A2 (en) 2008-11-26 2010-06-03 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using csf1r extracellular domain fusion molecules
EP2950098A1 (en) * 2009-07-14 2015-12-02 National Institute of Advanced Industrial Science and Technology Glycan markers as measure of disease state of hepatic diseases
MX378336B (es) 2010-05-04 2025-03-10 Five Prime Therapeutics Inc Anticuerpos que se unen a factor estimulante de colonias 1 (csf1r).
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
ES2442991B1 (es) * 2012-08-14 2014-11-25 Fundación Md Anderson International España Método para el diagnóstico y/o pronóstico de linfomas
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
AU2015280362B2 (en) 2014-06-23 2021-03-04 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
PT3212670T (pt) 2014-10-29 2021-02-15 Bristol Myers Squibb Co Terapêutica de combinação para cancro
EA201791421A1 (ru) 2014-12-22 2017-10-31 Файв Прайм Терапьютикс, Инк. Антитела против csf1r для лечения pvns
BR112017020952A2 (pt) 2015-04-13 2018-07-10 Five Prime Therapeutics Inc método de tratamento de câncer, composição e uso da composição
SG11202001606XA (en) 2017-09-13 2020-03-30 Five Prime Therapeutics Inc Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4929700A (en) * 1987-04-16 1990-05-29 Cetus Corporation Production of purified, biologically active, bacterially produced recombinant human CSF-1
AU2728588A (en) * 1987-10-23 1989-05-23 Genetics Institute Inc. Composition and method for treating cancers characterized by over-expression of the c-fms proto-oncogene
JPH0967400A (ja) * 1995-08-31 1997-03-11 Toray Ind Inc モノクローナル抗体、該抗体を産生するハイブリドーマ及びその利用
US6610484B1 (en) * 1999-01-26 2003-08-26 Cytyc Health Corporation Identifying material from a breast duct
WO2004045532A2 (en) * 2002-11-15 2004-06-03 Chiron Corporation Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
US20040209937A1 (en) * 2003-02-24 2004-10-21 Sugen, Inc. Treatment of excessive osteolysis with indolinone compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2427323C1 (ru) * 2010-02-25 2011-08-27 Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Федерального агентства по высокотехнологичной медицинской помощи" Способ прогнозирования генерализации процесса при злокачественных опухолях костей

Also Published As

Publication number Publication date
JP2009521685A (ja) 2009-06-04
AU2006342119A1 (en) 2007-10-25
JP2012108155A (ja) 2012-06-07
WO2007120252A3 (en) 2008-10-09
US20140030738A1 (en) 2014-01-30
EP1977238A2 (en) 2008-10-08
KR20080085054A (ko) 2008-09-22
AU2006342119B8 (en) 2013-05-09
AU2006342119A8 (en) 2013-05-09
AU2006342119B2 (en) 2013-01-10
CA2634945A1 (en) 2007-10-25
EP1977238B1 (en) 2016-09-28
KR101358600B1 (ko) 2014-02-06
WO2007120252A2 (en) 2007-10-25
US20100099123A1 (en) 2010-04-22

Similar Documents

Publication Publication Date Title
US20140030738A1 (en) Soluble human m-csf receptor and uses thereof
JP6411379B2 (ja) レンバチニブ化合物に対する子宮内膜がん対象の応答性を予測及び評価するためのバイオマーカー
CN110506209B (zh) 尿中所测的半乳凝素3结合蛋白用于监测狼疮性肾炎严重性和进展的应用方法
KR20050118690A (ko) 가스트린 호르몬 면역어세이
US12459997B2 (en) Compounds and methods targeting interleukin-19
RU2671578C2 (ru) Способ прогнозирования риска возникновения рака или диагностирования рака у женщины
JP2023508023A (ja) Ｃｘｃｌ１０結合タンパク質及びその使用
KR20180013878A (ko) 렌바티닙 및 에베로리무스를 포함하는 병용 요법을 위한 생체표지
CN108139404A (zh) 特异性地识别、结合活性结构的REIC/Dkk-3蛋白的抗体、以及使用该抗REIC/Dkk-3抗体的癌治疗的监测
EP2541249A1 (en) EpCAM detection
CN103558391A (zh) 可溶性人m-csf受体及其应用
US7892541B1 (en) Soluble epidermal growth factor receptor isoforms
JP2019518970A (ja) 腎臓癌を患う対象の癌治療に対する感受性を予測するための方法およびキット
AU2012261609A1 (en) Soluble human M-CSF receptor and uses thereof
CN119667163B (zh) Il-1r2在鉴定对象免疫状态中的应用
MX2008007881A (es) Receptor m-csf humano soluble y usos del mismo
WO2019064073A1 (en) USE OF CA125 FOR PREDICTING ANTI-MESOTHELIC TREATMENT OF MESOTHELIOMES
JP2008537101A (ja) 薬物応答を予測するための前立腺特異的抗原の使用
EP4473010A1 (en) Method for diagnosing collagen degradatation associated disease
JPWO2020101039A1 (ja) 血中ケモカインを用いた免疫チェックポイント阻害薬の治療効果判定
CN110546510A (zh) 预后方法和在所述方法中有用的试剂盒
HK1212762B (zh) 预测女性对象患癌症风险或诊断其癌症的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20090304